 |
Corporate News
10-May-24
|
|
|
|
|
|
|
|
|
|
|
|
Lupin commences shipment of Mirabegron ER Tablets to US
|
|
|
|
|
|
|
|
Lupin announced that the US Court has lifted the Temporary Restraining Order and denied Astellas' request for a preliminary injunction on Mirabegron ER Tablets. Thereafter, shipment of the
product has now resumed.
Mirabegron ER Tablets, 25 mg are a generic equivalent of Myrbetriq® Extended-Release Tablets, 25 mg of Astellas Pharma Global Development, Inc., and were launched by Lupin in April 2024.
|
|
|
|
Previous News |
Nanomi wins prestigious CMO Award for Life Science Leadership in Drug Delivery
(
Corporate News
-
21-Mar-25
19:12
)
|
|
|
Lupin allots 24,101 equity shares under ESOP
(
Corporate News
-
21-Mar-25
16:10
)
|
|
|
Lupin receives USFDA tentative approval for Amifampridine Tablets
(
Corporate News
-
17-Mar-25
13:36
)
|
|
|
Lupin gains after getting tentative USFDA approval for Amifampridine tablets 10 mg
(
Hot Pursuit
-
17-Mar-25
10:44
)
|
|
|
Lupin launches Rivaroxaban drug in US
(
Hot Pursuit
-
10-Mar-25
10:02
)
|
|
|
Lupin launches Rivaroxaban Tablets USP, 2.5 mg in the US
(
Corporate News
-
07-Mar-25
16:43
)
|
|
|
Lupin Ltd spurts 0.59%, up for five straight sessions
(
Hot Pursuit
-
06-Mar-25
13:00
)
|
|
|
Lupin allots 59,940 equity shares under ESOP
(
Corporate News
-
27-Feb-25
12:40
)
|
|
|
Indices drift lower in early trade; breadth weak
(
Market Commentary
-
Mid-Session
24-Feb-25
09:34
)
|
|
|
Stock Alert: Granules India, Lupin, Bharti Airtel, Hazoor Multi Projects, Lemon Tree Hotels
(
Market Commentary
-
Stock Alert
24-Feb-25
08:22
)
|
|
|
Lupin gets EIR from USFDA for New Jersey facility
(
Hot Pursuit
-
22-Feb-25
10:41
)
|
|
|
|
|
|
Other Stories |
|
|
|
|
|
|
|
|
|
|
|
|
|